Literature DB >> 11816787

Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's disease.

C Glabe1.   

Abstract

Cell-culture studies have revealed some of the fundamental features of the interaction of amyloid Abeta with cells and the mechanism of amyloid accumulation and pathogenesis in vitro. A(beta)1-42, the longer isoform of amyloid that is preferentially concentrated in senile plaque (SP) amyloid deposits in Alzheimer's disease (AD), is resistant to degradation and accumulates as insoluble aggregates in late endosomes or lysosomes. Once these aggregates have nucleated inside the cell, they grow by the addition of aberrantly folded APP and amyloidgenic fragments of APP, that would otherwise be degraded, onto the amyloid lattice in a fashion analogous to prion replication. This accumulation of heterogeneous aggregated APP fragments and Abeta appears to mimic the pathophysiologyof dystrophic neurites, where the same spectrum of components has been identified by immunohistochemistry. In the brain, this residue appears to be released into the extracellular space, possibly by a partially apoptotic mechanism that is restricted to the distal compartments of the neuron. Ultimately, this insoluble residue may be further digested to the protease-resistant A(beta)n-42 core, perhaps by microglia, where it accumulates as senile plaques. Thus, the dystrophic neurites are likely to be the source of the immediate precursors of amyloid in the senile plaques. This is the opposite of the commonly held view that extracellular accumulation of amyloid induces dystrophic neurites. Many of the key pathological events of AD may also be directly related to the intracellular accumulation of this insoluble amyloid. The aggregated, intracellular amyloid induces the production of reactive oxygen species (ROS) and lipid peroxidation products and ultimately results in the leakage of the lysosomal membrane. The breakdown of the lysosomal membrane may be a key pathogenic event, leading to the release of heparan sulfate and lysosomal hydrolases into the cytosol. Together, these observations provide the novel view that amyloid deposits and some of the early events of amyloid pathogenesis initiate randomly within single cells in AD. This pathogenic mechanism can explain some of the more enigmatic features of Alzheimer's pathogenesis, like the focal nature of amyloid plaques, the relationship between amyloid, dystrophic neurites and neurofibrillary-tangle pathology, and the miscompartmentalization of extracellular and cytosolic components observed in AD brain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11816787     DOI: 10.1385/JMN:17:2:137

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  91 in total

1.  Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene.

Authors:  M C Chartier-Harlin; F Crawford; H Houlden; A Warren; D Hughes; L Fidani; A Goate; M Rossor; P Roques; J Hardy
Journal:  Nature       Date:  1991-10-31       Impact factor: 49.962

2.  Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease.

Authors:  M R D'Andrea; R G Nagele; H Y Wang; P A Peterson; D H Lee
Journal:  Histopathology       Date:  2001-02       Impact factor: 5.087

3.  Ultrastructural localization of argyrophilic substances in diffuse plaques of Alzheimer-type dementia demonstrated by methenamine silver staining.

Authors:  T Yamazaki; H Yamaguchi; K Okamoto; S Hirai
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

4.  Dystrophic neurites around amyloid plaques of human patients with Gerstmann-Sträussler-Scheinker disease contain ubiquitinated inclusions.

Authors:  A Migheli; A Attanasio; M C Vigliani; D Schiffer
Journal:  Neurosci Lett       Date:  1991-01-02       Impact factor: 3.046

Review 5.  The immunopathology of Alzheimer's disease and some related disorders.

Authors:  R N Kalaria
Journal:  Brain Pathol       Date:  1993-10       Impact factor: 6.508

6.  Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation.

Authors:  M Citron; C Vigo-Pelfrey; D B Teplow; C Miller; D Schenk; J Johnston; B Winblad; N Venizelos; L Lannfelt; D J Selkoe
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

7.  Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein.

Authors:  M F Knauer; B Soreghan; D Burdick; J Kosmoski; C G Glabe
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

8.  Ultrastructural localization of Alzheimer amyloid beta/A4 protein precursor in the cytoplasm of neurons and senile plaque-associated astrocytes.

Authors:  H Yamaguchi; T Yamazaki; K Ishiguro; M Shoji; Y Nakazato; S Hirai
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

Review 9.  Radical AGEing in Alzheimer's disease.

Authors:  M A Smith; L M Sayre; V M Monnier; G Perry
Journal:  Trends Neurosci       Date:  1995-04       Impact factor: 13.837

10.  Kunitz protease inhibitor-containing amyloid beta protein precursor immunoreactivity in Alzheimer's disease.

Authors:  B T Hyman; R E Tanzi; K Marzloff; R Barbour; D Schenk
Journal:  J Neuropathol Exp Neurol       Date:  1992-01       Impact factor: 3.685

View more
  70 in total

1.  Inhibitors of catalase-amyloid interactions protect cells from beta-amyloid-induced oxidative stress and toxicity.

Authors:  Lila K Habib; Michelle T C Lee; Jerry Yang
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

Review 2.  Apoptotic mechanisms in Alzheimer neurofibrillary degeneration: cause or effect?

Authors:  Dennis W Dickson
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

3.  In vivo reduction of amyloid-beta by a mutant copper transporter.

Authors:  Amie L Phinney; Bettina Drisaldi; Stephen D Schmidt; Stan Lugowski; Veronica Coronado; Yan Liang; Patrick Horne; Jing Yang; Joannis Sekoulidis; Janaky Coomaraswamy; M Azhar Chishti; Diane W Cox; Paul M Mathews; Ralph A Nixon; George A Carlson; Peter St George-Hyslop; David Westaway
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-14       Impact factor: 11.205

4.  Neuritic deposits of amyloid-beta peptide in a subpopulation of central nervous system-derived neuronal cells.

Authors:  Zoia Muresan; Virgil Muresan
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

Review 5.  Beta-amyloid modulation of synaptic transmission and plasticity.

Authors:  Deepa V Venkitaramani; Jeannie Chin; William J Netzer; Gunnar K Gouras; Sylvain Lesne; Roberto Malinow; Paul J Lombroso
Journal:  J Neurosci       Date:  2007-10-31       Impact factor: 6.167

6.  Neurotoxic effects induced by the Drosophila amyloid-beta peptide suggest a conserved toxic function.

Authors:  Katia Carmine-Simmen; Thomas Proctor; Jakob Tschäpe; Burkhard Poeck; Tilman Triphan; Roland Strauss; Doris Kretzschmar
Journal:  Neurobiol Dis       Date:  2008-11-08       Impact factor: 5.996

7.  Signal transduction in Alzheimer disease: p21-activated kinase signaling requires C-terminal cleavage of APP at Asp664.

Authors:  Thuy-Vi V Nguyen; Veronica Galvan; Wei Huang; Surita Banwait; Huidong Tang; Junli Zhang; Dale E Bredesen
Journal:  J Neurochem       Date:  2007-11-06       Impact factor: 5.372

8.  Novel mediators of amyloid precursor protein signaling.

Authors:  Andrzej Swistowski; Qiang Zhang; Mark E Orcholski; Danielle Crippen; Cathy Vitelli; Alexei Kurakin; Dale E Bredesen
Journal:  J Neurosci       Date:  2009-12-16       Impact factor: 6.167

9.  Apoptosis and in vitro Alzheimer disease neuronal models.

Authors:  P Calissano; C Matrone; G Amadoro
Journal:  Commun Integr Biol       Date:  2009

10.  The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease.

Authors:  Yasuo Ihara; Maho Morishima-Kawashima; Ralph Nixon
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.